Top Industry Leaders in the Fibrocystic Breasts Diagnostics Treatment Market
Latest Fibrocystic Breasts Diagnostics and Treatment Companies Update
Contrast-enhanced spectral mammography (CESM) new technology is gaining traction for its ability to better visualize blood flow within breast lesions, potentially helping distinguish benign fibrocystic changes from malignant tumors. Companies like Siemens Healthineers are actively developing and introducing CESM systems.
3D tomosynthesis advanced mammogram technique provides detailed 3D images of the breast, aiding in differentiating complex structures like fibrocystic changes and reducing the risk of overlapping tissue obscuring potentially suspicious lesions.List of Fibrocystic Breasts Diagnostics and Treatment Key Companies in the Market
- Argon Medical Devices
- Boston Scientific
- CareFusion Corporation (Acquired by Becton, Dickinson and Company)
- C. R. Bard, Inc
- Cook Medical
- Devicor Medical Products Inc.
- Gallini Medical Devices
- Hologic, Inc.
- INRAD, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd
- Bayer AG
- Allergan plc.